# Vascular Surgery Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ella Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML029-SYN
- Date: 2026-05-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marcus Okafor-Lane, MD
- Calendar frame: modern shifted

- Requested by: Odessa Whitlow, MD

## Reason for consultation

Claudication of both calves, worse on the right, in a 70-year-old touring singer with type 2 diabetes, coronary bypass surgery last year, and an ankle-brachial index of 0.62 right and 0.74 left. Please define the arterial disease, advise on exercise and antithrombotic therapy, and tell us whether and when revascularization should be considered, so that her limbs are protected before any tissue is lost. **S**

## History

Ms. Fitzgerald, a 70-year-old singer, is seen at the request of Dr. Whitlow for calf pain on walking. For about a year both calves have cramped after one and a half blocks, the right sooner, easing within minutes of rest; she uses a wheelchair in large airports. She has no pain at rest or at night, no wounds, and no color change. She had five-vessel coronary bypass surgery last year and has no angina. She has diabetes with retinopathy and has never smoked. She has had no bleeding problems. She stands through long sets on stage and wants to keep touring. **S**

## Examination

| System | Finding |
|---|---|
| Vascular | Femoral pulses present and equal; popliteal and foot pulses absent on the right; foot pulses faint on the left; no bruits over the abdomen |
| Feet | Warm; slow capillary refill on the right; no pallor on elevation or dependent rubor; skin intact; calluses and hammer toes; no ulcer or gangrene |
| Neurological | Protective sensation intact to the monofilament |

BP 124/70 mmHg; pulse 60 bpm; respirations 16/min; temperature 36.5 °C; oxygen saturation 97% on room air; weight 83.8 kg; BMI 30.8 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Whitlow's intake note and today's two-week note. Ankle-brachial index 0.62 right and 0.74 left; toe-brachial index 0.46 and 0.55. Creatinine 0.92 mg/dL, eGFR 67; hemoglobin 12.4 g/dL; LDL 92 mg/dL; A1c 8.6%. Arterial duplex in the vascular laboratory today: aortoiliac and common femoral arteries without significant narrowing; right superficial femoral artery occluded for about 9 cm in its middle third, with flow restored in the above-knee popliteal artery and two open tibial arteries to the foot; left superficial femoral artery narrowed by 50 to 69% with an open popliteal artery and three tibial arteries; calcified tibial arteries on both sides. 

## Assessment

1. **Type 2 diabetes with peripheral artery disease** (E11.51). Femoropopliteal peripheral artery disease in both legs: a right superficial femoral artery occlusion and a moderate left superficial femoral artery stenosis, with good flow to the feet. She has lifestyle-limiting claudication without signs of chronic limb-threatening ischemia (no rest pain, wound, or gangrene), so the limb is not at immediate risk. The first steps are supervised exercise therapy and medical therapy, which improve walking and lower the risk of heart attack, stroke, and limb events. Revascularization is considered when claudication still limits her life after a trial of exercise and medicines, and urgently if a wound, rest pain, or color change appears. Because amputation is more common in people with diabetes, and more common still, and more often done without a vascular assessment first, in Black Americans and in people with less access to care, she should have a low threshold for prompt vascular review of any foot problem. **S**
2. **Coronary artery disease after bypass surgery** (I25.10). Disease in two vascular beds. Low-dose rivaroxaban with aspirin lowers the risk of major cardiovascular and limb events in symptomatic peripheral artery disease, and her bleeding risk is low (no earlier bleeding, normal hemoglobin and kidney function, no anti-inflammatory painkillers). **S**

## Recommendations

1. No revascularization now.
2. Supervised exercise therapy: treadmill walking to moderate calf pain, 30 to 45 minutes three times a week for twelve weeks, with a structured home walking plan for tour weeks.
3. Start rivaroxaban 2.5 mg twice daily with aspirin 81 mg daily; avoid anti-inflammatory painkillers.
4. Continue atorvastatin 80 mg and add ezetimibe if LDL stays at 55 mg/dL or above; a GLP-1 receptor agonist such as semaglutide, which increased walking distance in people with peripheral artery disease and type 2 diabetes, is worth considering when her glucose plan is reviewed.
5. Reassess after twelve weeks of exercise; if claudication still limits her life, consider endovascular treatment of the right superficial femoral artery.
6. Urgent vascular review, the same or next day, for rest pain, a foot wound that does not heal within two weeks, or a cold, pale, or dark toe.
7. Vascular review with ankle-brachial index and duplex in six months, and yearly after that if stable.
8. High-risk foot program with podiatry every three months and protective, low-heeled shoes on and off stage.

## Strengths and supports

- Supports and strengths: her music, her audiences, her band and road manager, and decades of experience of her own body on the road **S**

## Communication

Discussed with Dr. Whitlow, who saw her the same day. The findings and choices were explained to Ms. Fitzgerald, who chose to begin supervised exercise and rivaroxaban; she decides who else receives this note. **S**

## Follow-up

Message review with Dr. Whitlow after twelve weeks of supervised exercise; vascular clinic in six months with ankle-brachial index and duplex; sooner for any of the urgent signs. **S**

## Guideline basis

- Standards of Care in Diabetes—2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023), International Working Group on the Diabetic Foot (Diabetes Metab Res Rev 2024)
- The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer (2023), IWGDF, European Society for Vascular Surgery, and Society for Vascular Surgery (Diabetes Metab Res Rev 2024)
- 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024), American College of Cardiology and American Heart Association (Circulation 2024)
- Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial (2025), The Lancet (Bonaca MP, et al.)
